Swati A. Kulkarni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Swati A. Kulkarni has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Bastien Nguyen
Eli Lilly and Company, Indianapolis, IN
4 shared publications - Claudia Karacsonyi
19Loxo@Lilly, Lilly Corporate Center, Indianapolis, Indiana
4 shared publications David Schacht
Department of Radiology Northwestern University Feinberg School of Medicine Chicago Illinois USA
4 shared publications- Duncan Wheatley
13Royal Cornwall Hospital, Truro, United Kingdom
4 shared publications - Erika Hamilton
Sarah Cannon Research Institute, Nashville, TN, USA
4 shared publications - Eunice Yuen
Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, United Kingdom
4 shared publications
Latest Publications
- Open Access
- 3 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (1) , 33-42
Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers
Purpose: A qualitative focus group study was conducted to explore the perceived motivators and barriers to clinical trial participation from the perspective of women at risk for ductal carcinoma in situ (DCIS), women with a history of DCIS, and healthcare providers who care for patients with DCIS to improve recruitment to a prospective multicenter randomized prospective window of opportunity study of a tissue selective estrogen complex in postmenopausal women with DCIS. Methods: Qualitative thematic analysis was applied to six online focus groups. The perceived motivators and barriers to participation in DCIS presurgical trials were assessed across groups. Baseline knowledge of DCIS and attitudes toward postmenopausal hormone therapies were also evaluated. Analysis was completed in NVivo. Results: Potential DCIS pre-surgical trial participants were motivated by altruism, receiving better care, and increased monitoring by the healthcare team. Conversely, the potential for the study drug to cause harm, distrust in the medical field, and the non-life-threatening nature of DCIS were barriers to participation in pre-surgical trial. Healthcare providers felt that participants were motivated by financial incentives and receiving better care. Surgical delays, an ineffective intervention, and participant anxiety were seen as barriers to participation. Conclusion: There was overlap in the perceived motivators and barriers to participation in a pre-surgical trial among women with a history of DCIS and at-risk women. However, healthcare providers identified differing perceived patient motivators and barriers from these groups, indicating that a greater understanding among health care providers of patient motivators and barriers may facilitate recruitment to DCIS pre-surgical trials.
- 3 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (1) , 33-42
Open AccessBarriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers
Purpose: A qualitative focus group study was conducted to explore the perceived motivators and barriers to clinical trial participation from the perspective of women at risk for ductal carcinoma in situ (DCIS), women with a history of DCIS, and healthcare providers who care for patients with DCIS to improve recruitment to a prospective multicenter randomized prospective window of opportunity study of a tissue selective estrogen complex in postmenopausal women with DCIS. Methods: Qualitative thematic analysis was applied to six online focus groups. The perceived motivators and barriers to participation in DCIS presurgical trials were assessed across groups. Baseline knowledge of DCIS and attitudes toward postmenopausal hormone therapies were also evaluated. Analysis was completed in NVivo. Results: Potential DCIS pre-surgical trial participants were motivated by altruism, receiving better care, and increased monitoring by the healthcare team. Conversely, the potential for the study drug to cause harm, distrust in the medical field, and the non-life-threatening nature of DCIS were barriers to participation in pre-surgical trial. Healthcare providers felt that participants were motivated by financial incentives and receiving better care. Surgical delays, an ineffective intervention, and participant anxiety were seen as barriers to participation. Conclusion: There was overlap in the perceived motivators and barriers to participation in a pre-surgical trial among women with a history of DCIS and at-risk women. However, healthcare providers identified differing perceived patient motivators and barriers from these groups, indicating that a greater understanding among health care providers of patient motivators and barriers may facilitate recruitment to DCIS pre-surgical trials.
- Open Access
- 27 April 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (5)
Pleomorphic Adenoma in the Setting of Triple‐Negative Breast Cancer: A Case Report
We report a case of a patient‐detected breast mass that revealed invasive carcinoma adjacent to a pleomorphic adenoma, which was treated with wide local excision. This case report highlights the importance of careful pathologic evaluation to guide appropriate local and systemic therapy and avoid the potentially harmful effects of overtreatment.
- 27 April 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (5)
Open AccessPleomorphic Adenoma in the Setting of Triple‐Negative Breast Cancer: A Case Report
We report a case of a patient‐detected breast mass that revealed invasive carcinoma adjacent to a pleomorphic adenoma, which was treated with wide local excision. This case report highlights the importance of careful pathologic evaluation to guide appropriate local and systemic therapy and avoid the potentially harmful effects of overtreatment.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose:Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study.Patients and Methods:Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed.Results:Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose.Conclusions:EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose:Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study.Patients and Methods:Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed.Results:Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose.Conclusions:EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Table depicting the study population
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Table depicting the study population
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Plasma imlunestrant concentrations at visit 2
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Plasma imlunestrant concentrations at visit 2
- Open Access
- 8 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5304-5313
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- 8 October 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (23) , 5304-5313
Open AccessA Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Purpose: Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study. Patients and Methods: Postmenopausal women with untreated, operable estrogen receptor (ER)–positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed. Results: Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose. Conclusions: EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
- 1 August 2024
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 159 (8) , 863-864
Bariatric Surgery Reduces Breast Cancer Incidence in a Prospective Trial
In this issue of JAMA Surgery, Kristensson et al build on their previous research using participants from the Swedish Obese Subjects Study (SOS), a
- 1 August 2024
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 159 (8) , 863-864
Bariatric Surgery Reduces Breast Cancer Incidence in a Prospective Trial
In this issue of JAMA Surgery, Kristensson et al build on their previous research using participants from the Swedish Obese Subjects Study (SOS), a
- Open Access
- 22 June 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (9) , 5489-5490
From Input to Impact: Clinical Significance of Data Quality in the National Cancer Database
- 22 June 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (9) , 5489-5490
Open AccessFrom Input to Impact: Clinical Significance of Data Quality in the National Cancer Database
- Open Access
ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer
- 26 December 2023
- Published by Elsevier in Clinical Breast Cancer
- Vol. 24 (4) , 292-300
Update on Management of Ductal Carcinoma in Situ
- 26 December 2023
- Published by Elsevier in Clinical Breast Cancer
- Vol. 24 (4) , 292-300
Update on Management of Ductal Carcinoma in Situ